000			01620na a2200241 4500
003			PC9227
005			20180417112756.0
008			130622s2012 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aOrtiz Romero, Pablo Luis _91223 _eDermatología Médico-Quirúrgica y Venereología
100			_aRosales Trujillo, Belén _91228 _eDermatología Médico-Quirúrgica y Venereología
245	0	0	_aIntralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma. _h[artículo]
260			_bThe British journal of dermatology, _c2012
300			_a167(1):174-9.
500			_aFormato Vancouver: Peñate Y, Hernández-Machín B, Pérez-Méndez LI, Santiago F, Rosales B, Servitje O, et al. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma. Br J Dermatol. 2012 Jul;167(1):174-9.
501			_aPMID: 22356294
504			_aContiene 12 referencias
520			_aBACKGROUND: Intravenous rituximab is a safe and effective option for the treatment of systemic non-Hodgkin B-cell lymphoma. The effectiveness of intralesional rituximab (ILR) in primary cutaneous B-cell lymphomas (PCBL) has been described in a small number of patients.
710			_9145 _aServicio de Dermatología Médico-Quirúrgica y Venereología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/9/pc9227.pdf _ySolicitar documento
942			_n0 _2ddc _cART
999			_c9227 _d9227